Carbon Nanomaterials for Theranostic Use
Based on statistics from the National Cancer Institute in the US, the rate of new cases of cancer is 442.4 per 100,000 men and women per year, and more than one-third do not survive the disease. Cancer diagnosis and treatment are the most important challenges in modern medicine. The majority of canc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | C |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2311-5629/8/1/3 |
| _version_ | 1797472433560616960 |
|---|---|
| author | Izabela Kościk Daniel Jankowski Anna Jagusiak |
| author_facet | Izabela Kościk Daniel Jankowski Anna Jagusiak |
| author_sort | Izabela Kościk |
| collection | DOAJ |
| description | Based on statistics from the National Cancer Institute in the US, the rate of new cases of cancer is 442.4 per 100,000 men and women per year, and more than one-third do not survive the disease. Cancer diagnosis and treatment are the most important challenges in modern medicine. The majority of cancer cases are diagnosed at an early stage. However, the possibility of simultaneous diagnosis and application of therapy (theranostics) will allow for acceleration and effectiveness of treatment. Conventional chemotherapy is not effective in reducing the chemoresistance and progression of various types of cancer. In addition, it causes side effects, which are mainly a result of incorrect drug distribution. Hence, new therapies are being explored as well as new drug delivery strategies. In this regard, nanotechnology has shown promise in the targeted delivery of therapeutics to cancer cells. This review looks at the latest advances in drug delivery-based diagnosis and therapy. Drug delivery nanosystems made of various types of carbon (graphene, fullerenes, and carbon nanotubes) are discussed. Their chemical properties, advantages, and disadvantages are explored, and these systems are compared with each other. |
| first_indexed | 2024-03-09T20:02:39Z |
| format | Article |
| id | doaj.art-2e441b6c38c942b887e487350ba9b506 |
| institution | Directory Open Access Journal |
| issn | 2311-5629 |
| language | English |
| last_indexed | 2024-03-09T20:02:39Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | C |
| spelling | doaj.art-2e441b6c38c942b887e487350ba9b5062023-11-24T00:41:16ZengMDPI AGC2311-56292021-12-0181310.3390/c8010003Carbon Nanomaterials for Theranostic UseIzabela Kościk0Daniel Jankowski1Anna Jagusiak2Chair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kopernika 7, 31-034 Krakow, PolandFaculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, PolandChair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kopernika 7, 31-034 Krakow, PolandBased on statistics from the National Cancer Institute in the US, the rate of new cases of cancer is 442.4 per 100,000 men and women per year, and more than one-third do not survive the disease. Cancer diagnosis and treatment are the most important challenges in modern medicine. The majority of cancer cases are diagnosed at an early stage. However, the possibility of simultaneous diagnosis and application of therapy (theranostics) will allow for acceleration and effectiveness of treatment. Conventional chemotherapy is not effective in reducing the chemoresistance and progression of various types of cancer. In addition, it causes side effects, which are mainly a result of incorrect drug distribution. Hence, new therapies are being explored as well as new drug delivery strategies. In this regard, nanotechnology has shown promise in the targeted delivery of therapeutics to cancer cells. This review looks at the latest advances in drug delivery-based diagnosis and therapy. Drug delivery nanosystems made of various types of carbon (graphene, fullerenes, and carbon nanotubes) are discussed. Their chemical properties, advantages, and disadvantages are explored, and these systems are compared with each other.https://www.mdpi.com/2311-5629/8/1/3graphenegraphene family nanomaterials (GFNs)nano-graphene oxide (NGO)graphene oxide (GO)reduced graphene oxide (R-GO)photosensitizer (PS) |
| spellingShingle | Izabela Kościk Daniel Jankowski Anna Jagusiak Carbon Nanomaterials for Theranostic Use C graphene graphene family nanomaterials (GFNs) nano-graphene oxide (NGO) graphene oxide (GO) reduced graphene oxide (R-GO) photosensitizer (PS) |
| title | Carbon Nanomaterials for Theranostic Use |
| title_full | Carbon Nanomaterials for Theranostic Use |
| title_fullStr | Carbon Nanomaterials for Theranostic Use |
| title_full_unstemmed | Carbon Nanomaterials for Theranostic Use |
| title_short | Carbon Nanomaterials for Theranostic Use |
| title_sort | carbon nanomaterials for theranostic use |
| topic | graphene graphene family nanomaterials (GFNs) nano-graphene oxide (NGO) graphene oxide (GO) reduced graphene oxide (R-GO) photosensitizer (PS) |
| url | https://www.mdpi.com/2311-5629/8/1/3 |
| work_keys_str_mv | AT izabelakoscik carbonnanomaterialsfortheranosticuse AT danieljankowski carbonnanomaterialsfortheranosticuse AT annajagusiak carbonnanomaterialsfortheranosticuse |